CEP 217
Latest Information Update: 26 Oct 2011
At a glance
- Originator Cephalon
- Class Anti-ischaemics; Neuroprotectants; Nootropics
- Mechanism of Action Phospholipase A2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cerebral ischaemia; Neurological disorders
Most Recent Events
- 26 Mar 2007 Discontinued - Preclinical for Cerebral ischaemia in USA (unspecified route)
- 26 Mar 2007 Discontinued - Preclinical for Neurological disorders in USA (unspecified route)
- 02 Oct 1996 No-Development-Reported for Cerebral ischaemia in USA (Unknown route)